CAR T-cell therapy is starting to enter the treatment conversations sooner with patients with multiple myeloma, according to ...

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

Antonio Jimenez Jimenez, MD, discusses the ACCESS trial of PTCy-based GVHD prophylaxis after mismatched unrelated donor stem cell transplantation.

Researchers working on an incurable blood cancer can now use a new lab model that could make testing potential new treatments ...

A study published in Cell Stem Cell reveals that some mutations in blood stem cells might help protect against late-onset ...